# Sanofi

Sanofi is a Corporate Investor based in Paris, France.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Paris, France
- **Region:** Europe
- **Address:** 54, Rue La Boétie, Paris, France
- **Founded:** 1973
- **Assets under management:** Undisclosed
- **Website:** sanofi.com
- **Wikidata:** Q158205

## Regulatory record

- **Reports private funds:** No

## About

Sanofi is a France-based life science organisation founded in 2004. It develops pharmaceutical products and vaccines, and works to improve access to healthcare services. Sanofi Ventures, its venture capital arm, invests in biotech and digital health companies from Seed to Series B and beyond.

## Sectors

- Digital Health
- AI/ML
- Biotechnology

## Offices

- Morristown, NJ, United States
- Cambridge, MA, United States

## People

- Paul Hudson — Chief Executive Officer

## Questions

### Who makes investment decisions for Sanofi's venture activities?

Investment and partnership decisions ultimately roll up to CEO Paul Hudson, who has driven the firm's strategic pivot since 2019. Day-to-day execution is managed through the business development and R&D leadership teams. Sanofi does not operate a standalone, publicly branded venture-capital arm; instead, equity stakes and collaboration agreements are negotiated within the therapeutic-area teams, giving scientific leads significant influence over which platform companies receive capital.

### What investment stages does Sanofi target?

Sanofi targets preclinical and clinical-stage biotech companies working in its priority therapeutic areas: immunology, oncology, rare disease, and vaccines. The firm also invests in platform and enabling-technology companies that support drug discovery, manufacturing, and artificial intelligence applied to clinical development. It generally enters after a platform is scientifically de-risked but before Phase III trials, when structured collaboration economics are most beneficial to both parties.

### What therapeutic areas does Sanofi explicitly avoid?

Sanofi's recent restructuring explicitly lowered priority on mature primary-care products and consumer health, a unit it moved to separate. The firm has not publicly identified therapeutic areas it will absolutely never invest in, but the stated pipeline focus on specialty care, vaccines, and rare disease signals reduced appetite for commoditized small-molecule categories or over-the-counter brands where its manufacturing advantages do not apply.

### How is Sanofi's manufacturing footprint relevant to its investment strategy?

Sanofi's "EVolutive Facilities" in France and Singapore are designed to switch production between multiple biologic products quickly. This flexibility gives the firm an edge in structuring venture deals: it can offer a potential partner not just capital but guaranteed production capacity upon regulatory success. Many biotech start-ups lack the balance sheet to build their own manufacturing, making Sanofi's combined capital-and-capacity offer distinctive in venture-stage negotiations.

## Related profiles

- [Sanlam Staff Umbrella Provident Fund](https://altss.com/profile/sanlam-staff-umbrella-provident-fund)
- [Sanrio Pension Fund](https://altss.com/profile/sanrio-pension-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/sanofi

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology